|View printer-friendly version|
|OpGen Strengthens Supplier Relationship to Use Industry-Leading Real-Time PCR Technology for New Acuitas® Tests|
Recent studies have indicated that antimicrobial resistant infections currently claim 50,000 lives each year across
Effective, targeted antimicrobial treatment is of critical importance in patients with cUTI and other serious infections as the emergence and spread of antimicrobial-resistant organisms increase. There are an estimated 400,000 to 800,000 patients each year in the U.S. with cUTI, and approximately half are at risk for multidrug-resistant infections. Complicated UTI continues to be a major cause of hospital admission, morbidity, mortality and excess health care costs as a growing number of infections are healthcare associated in origin.
In an easy-to-use laboratory protocol, the
“We are pleased to expand our relationship to include these market-leading real-time PCR technologies. In 2017 we entered into an agreement to use the QuantStudio™ 5 Real-Time PCR System. The combination of these technologies, along with OpGen’s innovative solutions, will aid laboratories and healthcare providers in the fight against antimicrobial resistance,” said
TaqMan® Fast Advanced Master Mix, TaqMan® Probes and QuantStudio™ 5 Real-Time PCR System are for research use only and are not intended for diagnostic procedures.